APA (7th ed.) Citation

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., . . . Weisel, K. (2022). Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): An open-label, multicentre, randomised, phase 3 trial. The lancet. Haematology, 9(6), . https://doi.org/10.1016/S2352-3026(22)00103-X

Chicago Style (17th ed.) Citation

Dimopoulos, Meletios A., et al. "Addition of Elotuzumab to Lenalidomide and Dexamethasone for Patients with Newly Diagnosed, Transplantation Ineligible Multiple Myeloma (ELOQUENT-1): An Open-label, Multicentre, Randomised, Phase 3 Trial." The Lancet. Haematology 9, no. 6 (2022). https://doi.org/10.1016/S2352-3026(22)00103-X.

MLA (9th ed.) Citation

Dimopoulos, Meletios A., et al. "Addition of Elotuzumab to Lenalidomide and Dexamethasone for Patients with Newly Diagnosed, Transplantation Ineligible Multiple Myeloma (ELOQUENT-1): An Open-label, Multicentre, Randomised, Phase 3 Trial." The Lancet. Haematology, vol. 9, no. 6, 2022, https://doi.org/10.1016/S2352-3026(22)00103-X.